8-K current report · filed Jun 17, 2026

CME Group (CME) 8-K Current Report: June 17, 2026

Item 5.02Item 7.01Item EX-99.1CME overview

Short answer

CME Group (CME) filed an 8-K current report with the SEC on June 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Terrence Duffy becomes Executive Chairman; Lynne Fitzpatrick succeeds him as CEO effective March 1, 2027, or 2026 Form 10-K filing date.

CME Group 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Terrence Duffy becomes Executive Chairman; Lynne Fitzpatrick succeeds him as CEO effective March 1, 2027, or 2026 Form 10-K filing date
  • Duffy remains CEO through transition, then supports continuity as Executive Chairman through December 31, 2027
  • Fitzpatrick’s CEO package includes $1.2 million salary, 200% bonus opportunity, and 700% long-term incentive opportunity
  • Company will search for Fitzpatrick’s successor as CFO, creating an additional executive leadership transition
  • Duffy’s equity awards generally vest at target upon transition, subject to release, increasing near-term compensation expense risk

Item 7.01 · Regulation FD Disclosure

  • CME furnished a June 17, 2026 press release concerning a leadership transition
  • Leadership change may affect CME’s strategic direction, execution priorities and investor expectations
  • Exhibit 99.1 contains the substantive transition details for investor review

Item EX-99.1 · Exhibit EX-99.1

  • CEO succession effective March 1, 2027: Lynne Fitzpatrick replaces Terry Duffy and joins CME Group’s board
  • Duffy transitions to Executive Chairman, preserving strategic continuity after more than 25 years as CEO
  • Fitzpatrick brings 20 years at CME Group, including President and CFO roles since 2024
  • Leadership transition follows 28.1 million average daily contracts and market capitalization above $95 billion last year
  • Investor focus: execution under new CEO while Duffy retains board-level influence and industry relationships

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CME Group 8-K filings

Get the next CME 8-K as it lands

Follow CME for push alerts, or ask the research agent what this filing means.